KO vs PFE: Which Is the Better Buy?

Side-by-side comparison of The Coca-Cola Company and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-06-20.

The Coca-Cola Company · Consumer Defensive

$79.39

-9.9% upside to fair value

Grade D High Quality

PFE

Pfizer Inc. · Healthcare

$25.22

+2.8% upside to fair value

Grade B

QuantHub Verdict

PFE has more upside to fair value (+2.8%). PFE trades at a lower forward P/E (19.2x). These are model outputs — not personalized investment advice. See all research →

Valuation & Fundamentals

Metric	KO	PFE
Current Price	$79.39	$25.22
Fair Value Estimate	$71.54	$25.92
Upside to Fair Value	-9.9%	+2.8%
Market Cap	$341.6B	$143.7B
Forward P/E	24.9x	19.2x
EV / EBITDA	19.5x	12.3x
Price / Sales	6.9x	2.3x
Price / FCF	27.2x	15.2x
Revenue Growth YoY	+12.1%	+5.4%
Gross Margin	61.7%	69.3%
Operating Margin	29.3%	23.4%
Return on Equity	43.6%	8.4%
Dividend Yield	0%	0%
FCF Yield	3.68%	6.6%
Analyst Consensus	Strong Buy	Hold

Investment Thesis

KO — The Coca-Cola Company

The Coca-Cola Company is a leading global branded beverages company with a very wide moat in sparkling soft drinks and non-alcoholic ready-to-drink beverages. It benefits from strong pricing power, stable margins, and high recurring cash flow, supported by a seasoned management team with deep company tenure. Despite solid recent growth with revenue up 12.1% and earnings up 17.8% in the most recen…

PFE — Pfizer Inc.

Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…

Accumulation Zones

Metric	KO	PFE
Zone Low	$53.66	$19.44
Zone High	$60.81	$22.03
In Buy Zone?	No	No

← KO Research PFE Research → All Research